Pegvisomant, a growth hormone receptor (GHR) antagonist, is a well-known drug that was designed to treat acromegaly. However, recent studies have indicated that the GHR is a moonlighting protein that may exhibit dual functions based on its localization in the plasma membrane and nucleus.
Molekulargewicht:
28.8 kDa (predicted). Due to glycosylation, the protein migrates to 45-60 kDa based on Tris-Bis PAGE result.
TMPK-00806
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten